A Phase 1/2 interventional study of Mesenchymal stem cells(HucMSCs) and CABG in Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure and Chronic Ischemic Cardiomyopathy, sponsored by Tasly Pharmaceutical Group Co., Ltd. Recruiting at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-09.
Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 376 studies in Heart Failure with a site in China — 162 open to participants now, 183 under way, 18 of them phase 3. Heart Failure · China.
Among the 376 studies in Heart Failure with a site in China, this one is the 188th largest by planned enrollment of the 246 interventional ones that give a count, is one of 35 that started in 2025, is one of 14 in phase 1/2, reaches primary completion later than 81 of the 182 other live ones, and was the 319th registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →162 of the 376 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
376 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 29
First in 1983; this study’s year is marked. 35 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 51 is below the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Median enrollment 127 across the 246 interventional studies, 554 across the 130 observational. Of the 115 that completed or were terminated, 33 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 376 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tasly Pharmaceutical Group Co., Ltd, one of the names counted as China Resources Pharmaceutical Group Limited. Under that name alone:
Tasly Pharmaceutical Group Co., Ltd is the lead sponsor of 32 studies on the registry; 17 are open to participants now.
China Resources Pharmaceutical Group Limited has 7 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
47 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 47 to your calendar (.ics) → With an account.
Among the 376 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater accessibility. The preliminary research results indicated that the B2278 injection promote the polarization of macrophages towards a reparative state through paracrine action, directly promote angiogenesis and inhibited inflammatory responses, thereby exerting effects on myocardial repair and treatment of heart failure, and it is also safe and well-tolerated.
This trial is a multi-center I/II phase clinical trial of the human umbilical cord mesenchymal stem cell injection solution, aiming to explore the dosage and regimen for the intramyocardial injection of B2278 in combination with coronary artery bypass grafting surgery for the treatment of chronic heart failure caused by chronic ischemic cardiomyopathy, and to evaluate the safety, tolerance and efficacy of allogeneic intramyocardial injection of the human umbilical cord mesenchymal stem cell injection solution in patients with chronic ischemic heart failure.
Inclusion Criteria:
Major exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CABG combined with B2278 at a dose of 1.0×10\^7 cells per patient, intramyocardial injection into the epicardium
Drug: Mesenchymal stem cells(HucMSCs)
CABG combined with B2278 at a dose of 5.0×10\^7 cells per patient, intramyocardial injection into the epicardium
Drug: Mesenchymal stem cells(HucMSCs)
CABG combined with B2278 at a dose of 2.0×10\^8 cells per patient, intramyocardial injection into the epicardium
Drug: Mesenchymal stem cells(HucMSCs)
Only CABG surgery
Procedure: CABG
B2278 is mesenchymal stem cells derived from human umbilical cord.
only CABG
In phase I, primary outcome will be measured with safety events including DLT, AE, SAE, TEAE, and MACE. In phase II, primary outcome will be measured with the change in LVEF based on CMR detection after 6 months of administration.
Time frame: 6 months
The changes in left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) on CMR compared to the baseline.
Time frame: 6 months
The changes from baseline of LVEF, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), LVEDV, LVESV on UCG
Time frame: 28 days, 3 months and 6 months
The proportion of participants with improved LVEF (the proportion of participants whose LVEF increased by ≥10% compared to the baseline and whose LVEF was >40% based on CMR and/or UCG);
Time frame: 3 months and 6 months
The distribution of the New York Heart Association (NYHA) cardiac function classification
Time frame: 28 days, 3 months and 6 months
The proportion of participants with NYHA classification ≤ II level
Time frame: 28 days, 3months and 6months
The changes in the 6-minute walk test (6MWT) results compared to the baseline
Time frame: 28 days, 3 months and 6months
The changes in the Minnesota Heart Failure Quality of Life Questionnaire (MLHFQ) from the baseline
Time frame: 28 days, 3months and 6months
The change in the result of amino-terminal pro-brain natriuretic peptide (NT-proBNP) compared to the baseline
Time frame: 28 days, 3months and 6months
The proportion of participants whose heart failure worsened (requiring hospitalization or emergency treatment due to the aggravation of heart failure symptoms and signs)
Time frame: 3 months and 6months
The change in troponin I (TnI) compared to the baseline
Time frame: 28 days, 3 months and 6months
The changes from the baseline of high-sensitivity C-reactive protein (hs-CRP), TNF-α, IL-1, and IL-6
Time frame: 28 days, 3 months and 6 months
The changes in perfusion and metabolism of ischemic myocardium during the injection stage as measured by myocardial nuclear imaging (SPECT + PET) compared to the baseline (applicable only to those who have undergone nuclear imaging for determination)
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 43 phase 1/2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tasly Pharmaceutical Group Co., Ltd →